Spyre Therapeutics, Inc. SYRE Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s net income?
- Spyre Therapeutics, Inc. (SYRE) reported net income of -$69.01M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s net income changed year-over-year?
- Spyre Therapeutics, Inc.'s net income decreased by 54.1% year-over-year, from -$44.77M to -$69.01M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s net income has grown at a 23.9% compound annual growth rate (CAGR), from -$65.8M to -$155.2M.
- What does net income mean?
- The final profit or loss remaining after all expenses are subtracted from total revenue.
- How do you interpret net income?
- Higher net income indicates improved profitability and operational efficiency, whereas a net loss suggests that the company is currently spending more than it earns, which is common for pre-revenue biotech companies.
- How does net income compare across companies?
- Most clinical-stage biotechnology companies report consistent net losses as they prioritize heavy investment in research and development over immediate profitability.